Sermorelin vs Ipamorelin
Sermorelin and ipamorelin are growth hormone secretagogues that stimulate endogenous GH release. Sermorelin is a GHRH analog with a recognized clinical history. Ipamorelin is a GH-releasing peptide with a cleaner side-effect signal and is often combined with CJC-1295 in compounded peptide therapy.
Sermorelin is appropriate when a GHRH-analog approach is provider-reviewed and a single-agent peptide pathway is preferred.
Explore pathwayIpamorelin is appropriate in select compounded peptide protocols and is not currently in the oMeds formulary.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Are these the same as HGH?
No — they stimulate endogenous GH release rather than supplying exogenous HGH.
How is candidacy determined?
Through a synchronous provider-reviewed assessment with IGF-1 and full biomarker context.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment